A new trading day began on Tuesday, with Denali Therapeutics Inc (NASDAQ: DNLI) stock price up 2.10% from the previous day of trading ,before settling in for the closing price of $19.04. DNLI’s price has ranged from $15.45 to $33.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 264.19% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -144.22%. With a float of $112.11 million, this company’s outstanding shares have now reached $138.39 million.
In an organization with 445 employees, it is important to assess its efficiency.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 19.44%, while institutional ownership is 78.37%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,896,250. In this transaction Director of this company sold 92,500 shares at a rate of $20.50, taking the stock ownership to the 47,341 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Director sold 1,666 for $20.10, making the entire transaction worth $33,487. This insider now owns 119,709 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
In its latest quarterly report, released on 12/30/2023, the company reported earnings of -$0.86 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -144.22% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Here are Denali Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.09, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.53 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.86 million. That was inferior than the volume of 1.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 36.59%. Additionally, its Average True Range was 0.99.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 47.48%, which indicates a significant increase from 34.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.67% in the past 14 days, which was lower than the 81.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.00, while its 200-day Moving Average is $21.52. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $19.83. Second resistance stands at $20.21. The third major resistance level sits at $20.67. If the price goes on to break the first support level at $18.98, it is likely to go to the next support level at $18.52. The third support level lies at $18.14 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
With a market capitalization of 2.71 billion, the company has a total of 139,160K Shares Outstanding. Currently, annual sales are 330,530 K while annual income is -145,220 K. The company’s previous quarter sales were 1,270 K while its latest quarter income was -99,350 K.
